Multiple manufacturers are producing quadrivalent influenza vaccine for the U.S. market for the 2023–24 season. Inactivated influenza vaccines (IIV4) will be produced using egg-based, cell culture-based, and recombinant technologies. Live attenuated nasal spray vaccine will also be available. Not all influenza vaccines are licensed for all age groups.
Immunize.org has a 1-page printable document that summarizes each of the products available for the current influenza vaccination season at www.immunize.org/catg.d/p4072.pdf.